Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

Inclusion Criteria:

Female patients with histologically confirmed adenocarcinoma of the breast or inflammatory breast cancer
Clinical stage T 1-4, N 0-3, M0
FISH+ HER2 gene amplified breast cancer
18 years or older
Normal cardiac function
Performance status 0-2
Cannot have received any prior chemotherapy for this disease or cannot have received chemotherapy for any other cancer in the past 5 years.
Previous diagnosis of noninvasive breast cancer is OK.
Must have adequate bone marrow, renal and liver function.
Pregnant or lactating females not allowed.
Preexisting peripheral neuropathy must be equal to or less than grade 1
Must have archived tumor tissue for tissue testing.

Exclusion Criteria:

You cannot be in this study if you any of the following:

History of cardiac disease, with New York Heart Association Class II or greater with congestive heart failure
Any heart attack, stroke or TIAs within the last 6 months or serious arrhythmias needing medication; no bleeding diathesis or coagulopathy.
No prior investigational drug within the last 30 days
No prior trastuzumab or bevacizumab therapy

There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons.